Protelos, first in new class of osteoporosis therapies launched today

Protelos (strontium ranelate), the only osteoporosis therapy to simultaneously increase bone formation and decrease bone resorption, was launched today by Servier Laboratories. The first in a new class of osteoporosis therapies called dual action bone agents (DABAs), Protelos is licenced for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral and hip fracture.

Recent Blog Post

Researchers challenge focus on rural older adults in Chris Whitty’s latest health report 

Tuesday 4th June – by Aaruthy Suthahar In a report published this week in Clinical Medicine, researchers from the Centre...

Study Reveals ZOE Personalised Diets Yield Health Improvements 

9th May 2024 – by Aaruthy Suthahar In a recent study published in the scientific journal Nature Medicine, researchers from...

New Study Reveals Epigenetic Markers for Type 2 Diabetes Complications in Identical Twins 

23rd April 2024 – by Aaruthy Suthahar A recent collaborative effort among seven international twin cohorts, including TwinsUK, has yielded...